VEGFD and colorectal carcinoma: Taken together, these two colorectal carcinoma studies showed that some patients with colorectal carcinoma developed high VEGF-D levels during VEGF-A inhibitor bevacizumab therapy, and increased VEGF-D might cause resistance to bevacizumab by switching the main source of VEGFR2 activation from VEGF-A to VEGF-D.